Zuellig Pharma, one of Asia’s leading healthcare solutions providers, has announced the upcoming launch of Mounjaro (tirzepatide) in Thailand by the end of May 2025. The once-weekly, dual-acting GLP-1/GIP receptor agonist, developed by Eli Lilly and Company, is a breakthrough therapy for the treatment of type 2 diabetes and obesity.
Zuellig Pharma holds the marketing authorization for Mounjaro in Thailand and has been entrusted by Eli Lilly with the distribution and promotional rights for this highly anticipated medication.
Mounjaro (tirzepatide) is approved for:
Available in the Mounjaro KwikPen format, the medicine comes in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths, enabling personalized treatment plans tailored to individual patient profiles.
Thailand faces a mounting healthcare crisis with:
These metabolic disorders contribute to a host of severe complications, including:
The Thai Ministry of Public Health has designated obesity as a Non-Communicable Disease (NCD) due to its strong correlation with chronic illnesses like type 2 diabetes.
Rehan Saghir, Executive Vice President of Commercialization at Zuellig Pharma, stated:
“Obesity and diabetes have gained prominence as significant health challenges in Thailand, and we are excited to accelerate the availability of Mounjaro® to patients in the region. With our deep understanding of the local regulatory landscape, as well as our proven track record in delivering innovative solutions, we are well placed to enhance accessibility in the chronic metabolic disease market.”
Zuellig Pharma’s commercialization and regulatory capabilities are expected to streamline market entry and scale adoption across both urban and rural healthcare settings.
Founded over 100 years ago, Zuellig Pharma is a multibillion-dollar healthcare services provider operating in 17 Asian markets with over 12,000 employees.
The company serves more than 200,000 medical facilities and partners with over 450 clients, including the world’s top 20 pharmaceutical companies. Its core mission is to make healthcare more accessible through innovative distribution, digital solutions, and commercial partnerships.
The launch of Mounjaro in Thailand is not just a new product rollout it’s a major public health milestone. With dual benefits for weight management and blood glucose control, tirzepatide addresses two of Thailand’s most pressing health crises simultaneously. Backed by Zuellig Pharma’s strong infrastructure and market reach, this launch is set to transform metabolic disease care in the region.